Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
hyperpolarized [13C]pyruvate + [15N]urea
- Development stage
- Unknown
- Lead developer
- University of California, San Francisco
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
Hyperpolarized [13C]pyruvate + [15N]urea is an investigational metabolic MRI imaging agent combination developed at the University of California, San Francisco (UCSF). It consists of two hyperpolarized stable-isotope labeled small molecules: [1-13C]pyruvate and [13C,15N2]urea. This diagnostic modality utilizes hyperpolarization to increase the MRI signal intensity by over 100,000-fold, allowing for real-time in vivo monitoring of tumor metabolism and perfusion. The pyruvate component is used to measure glycolytic flux, specifically the conversion of pyruvate to lactate (kPL), which is often elevated in aggressive tumors. The urea component serves as a perfusion marker to assess blood flow and vascularity within the tissue. It is currently being evaluated in Phase 2 clinical trials for patients with prostate cancer, particularly those undergoing or following radiation therapy, to assess treatment response and detect recurrence.
- Other names
- hyperpolarized 13C-pyruvate + 13C,15N-ureaHP 13C-pyruvate + 15N-ureahyperpolarized 13C-pyruvate + 13C,15N2-urea
02
Targets
LDH (L-lactate dehydrogenase A chain)
Beyond the preview
Go deeper on hyperpolarized [13C]pyruvate + [15N]urea.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on hyperpolarized [13C]pyruvate + [15N]urea.